Cheng Yu-Ting, Wu Meng-Yu, Chang Yu-Sheng, Huang Chung-Chi, Lin Pyng-Jing
Department of Cardiothoracic Surgery, Chang Gung Memorial Hospital School of Traditional Chinese Medicine Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Medicine (Baltimore). 2016 Jul;95(30):e4380. doi: 10.1097/MD.0000000000004380.
Despite gaining popularity, venovenous extracorporeal membrane oxygenation (VV-ECMO) remains a controversial therapy for acute respiratory failure (ARF) in adult patients due to its equivocal survival benefits. The study was aimed at identifying the preinterventional prognostic predictors of hospital mortality in adult VV-ECMO patients and developing a practical mortality prediction score to facilitate clinical decision-making.This retrospective study included 116 adult patients who received VV-ECMO for severe ARF in a tertiary referral center, from 2007 to 2015. The definition of severe ARF was PaO2/ FiO2 ratio < 70 mm Hg under advanced mechanical ventilation (MV). Preinterventional variables including demographic characteristics, ventilatory parameters, and severity of organ dysfunction were collected for analysis. The prognostic predictors of hospital mortality were generated with multivariate logistic regression and transformed into a scoring system. The discriminative power on hospital mortality of the scoring system was presented as the area under receiver operating characteristic curve (AUROC).The overall hospital mortality rate was 47% (n = 54). Pre-ECMO MV day > 4 (OR: 4.71; 95% CI: 1.98-11.23; P < 0.001), pre-ECMO sequential organ failure assessment (SOFA) score >9 (OR: 3.16; 95% CI: 1.36-7.36; P = 0.01), and immunocompromised status (OR: 2.91; 95% CI: 1.07-7.89; P = 0.04) were independent predictors of hospital mortality of adult VV-ECMO. A mortality prediction score comprising of the 3 binary predictors was developed and named VV-ECMO mortality score. The total score was estimated as follows: VV-ECMO mortality score = 2 × (Pre-ECMO MV day > 4) + 1 × (Pre-ECMO SOFA score >9) + 1 × (immunocompromised status). The AUROC of VV-ECMO mortality score was 0.76 (95% CI: 0.67-0.85; P < 0.001). The corresponding hospital mortality rates to VV-ECMO mortality scores were 18% (Score 0), 35% (Score 1), 56% (Score 2), 75% (Score 3), and 88% (Score 4), respectively.Duration of MV, severity of organ dysfunction, and immunocompromised status were important preinterventional prognostic predictors for adult VV-ECMO. The 3 prognostic predictors could also constitute a practical prognosticating tool in patients requiring this advanced respiratory support. Physicians in ECMO institutions are encouraged to perform external validations of this prognosticating tool and make contributions to score optimization.
尽管静脉-静脉体外膜肺氧合(VV-ECMO)越来越受欢迎,但由于其生存获益不明确,它仍是成年急性呼吸衰竭(ARF)患者存在争议的治疗方法。本研究旨在确定成年VV-ECMO患者住院死亡率的干预前预后预测因素,并制定一个实用的死亡率预测评分以促进临床决策。这项回顾性研究纳入了2007年至2015年在一家三级转诊中心因严重ARF接受VV-ECMO治疗的116例成年患者。严重ARF的定义为在高级机械通气(MV)下动脉血氧分压/吸入氧浓度(PaO2/FiO2)比值<70 mmHg。收集干预前的变量,包括人口统计学特征、通气参数和器官功能障碍的严重程度进行分析。通过多因素逻辑回归生成住院死亡率的预后预测因素,并将其转化为评分系统。评分系统对住院死亡率的判别能力以受试者工作特征曲线下面积(AUROC)表示。总体住院死亡率为47%(n = 54)。ECMO前MV天数>4天(比值比:4.71;95%置信区间:1.98 - 11.23;P<0.001)、ECMO前序贯器官衰竭评估(SOFA)评分>9分(比值比:3.16;95%置信区间:1.36 - 7.36;P = 0.01)和免疫功能低下状态(比值比:2.91;95%置信区间:1.07 - 7.89;P = 0.04)是成年VV-ECMO患者住院死亡率的独立预测因素。开发了一个由这3个二元预测因素组成的死亡率预测评分,并命名为VV-ECMO死亡率评分。总分估计如下:VV-ECMO死亡率评分 = 2×(ECMO前MV天数>4天) + 1×(ECMO前SOFA评分>9分) + 1×(免疫功能低下状态)。VV-ECMO死亡率评分的AUROC为0.76(95%置信区间:0.67 - 0.85;P<0.001)。与VV-ECMO死亡率评分相对应的住院死亡率分别为18%(评分0)、35%(评分1)、56%(评分2)、75%(评分3)和88%(评分4)。MV持续时间、器官功能障碍的严重程度和免疫功能低下状态是成年VV-ECMO重要的干预前预后预测因素。这3个预后预测因素也可以构成一种适用于需要这种高级呼吸支持患者的实用预后工具。鼓励ECMO机构的医生对这种预后工具进行外部验证,并为评分优化做出贡献。